Volume 2.28 | Jul 29

Cord Blood News 2.28, July 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events


Histone Deacetylase Regulates High Mobility Group A2-Targeting MicroRNAs in Human Cord Blood-Derived Multipotent Stem Cell Aging 
Researchers observed that the cellular senescence of human umbilical cord blood-derived multipotent stem cells caused by inhibition of histone deacetylase activity leads to down-regulation of high mobility group A2 and, on the contrary, to up-regulation of p16INK4A, p21CIP1/WAF1 and p27KIP1. [Cell Mol Life Sci]

MethoCult® Express: Request A Sample  
Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express
by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Prevalence and Predictors of Chronic Health Conditions After Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study
The burden of long-term morbidity borne by hematopoietic cell transplantation survivors is substantial, and long-term follow-up of patients who received transplantation is recommended. [Blood]

Allogeneic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative Acute Lymphocytic Leukemia: Comparable Survival Rates but Different Risk Factors Between Related and Unrelated Transplantation in First Complete Remission
Results showed comparable survival rates but different relapse rates, non-relapse mortality rates, and risk factors between related and unrelated allogeneic stem cell transplantations. [Blood]

Bone Marrow Transplantation Restores Epidermal Basement Membrane Protein Expression and Rescues Epidermolysis Bullosa Model Mice
Researchers aimed to clarify whether bone marrow transplantation treatment can rescue epidermolysis bullosa caused by defects in keratinocyte structural proteins. [Proc Natl Acad Sci U S A]

Epigenetic Upregulation of Urokinase Plasminogen Activator Promotes the Tropism of Mesenchymal Stem Cells for Tumor Cells
Researchers investigated whether histone deacetylation was involved in the repression of urokinase plasminogen activator expression in mesenchymal stem cells derived from umbilical cord blood and bone marrow. [Mol Cancer Res]

Galectin-3 Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Reduces Amyloid-Beta42 Neurotoxicity In Vitro
Researchers found that expression and secretion of galectin-3 were up-regulated by amyloid-beta42 exposure in human umbilical cord blood-derived mesenchymal stem cells without cell death. [FEBS Lett]

Ultrastructural Basis of Enhanced Antitumor Cytotoxicity of Cord Blood-Derived CTLs: A Comparative Analysis with Peripheral Blood and Bone Marrow
Results provide the comparative analyses of dendritic cells from cord blood, peripheral blood and bone marrow, and suggested that umbilical cord blood-dendritic cells might have better antigen presenting ability leading to increased cytotoxic T lymphocyte (CTL)-mediated antitumor cytotoxicity. [Int J Oncol]

Human Umbilical Cord Blood-Derived Stromal Cells Prevent Graft Versus Host Disease in Mice Following Haplo-Identical Stem Cell Transplantation
Results from a graft versus host disease mouse model are in agreement with previous in vitro findings, suggesting that human umbilical cord blood-derived stromal cells possess immunosuppressive properties and may act via influencing dendritic cells and CD4+ regulatory T cells. [Cytotherapy]

Haploidentical Stem Cell Transplantation as a Salvage Therapy for Cord Blood Engraftment Failure in a Patient with Fanconi Anemia
Haploidentical hematopoietic stem cell transplantations as primary or secondary sources of stem cells, with appropriate T-cell depletion, may be a readily available option in the absence of HLA-matched related or unrelated donors. [Pediatr Blood Cancer]

p38 Inhibitor Enhances Growth Inhibition and Death in Gallic Acid-Treated Endothelial Cells
Researchers investigated the effects of p38 inhibitor on gallic acid-induced calf pulmonary artery endothelial cells and human umbilical vein endothelial cell death in view of reactive oxygen species and glutathione. [Int J Mol Med]

The Therapeutic Potential of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Alzheimer’s Disease
Researchers undertook in vitro work to examine the potential impact of human umbilical cord blood-derived mesenchymal stem cell treatment on neuronal loss using a paradigm of cultured hippocampal neurons treated with amyloid-beta peptide. [Neurosci Lett]



STEMCELL Technologies Applauds Nature Protocol Article Published by Prominent HIV Lab at the Institut Pasteur Citing the Use of RoboSep® to Isolate CD4+ and CD8+ T Cells
In a recent, high-impact Nature Protocol publication, Asier Sáez-Cirión and his group at the Institut Pasteur standardized the protocol for T cell-based HIV suppression. RoboSep®, the fully automated cell separator from STEMCELL Technologies, was the instrument of choice for cell isolation procedures. [STEMCELL Technologies Inc. Press Release]

Cleveland LBO Firm Riverside Co. Buys Spanish Cord Blood Bank
Cleveland, Ohio leveraged buyout firm Riverside Co. has acquired private cord blood bank Celvitae Biomedica S.A. in Madrid, Spain for undisclosed terms. [MedCity News]

International Stem Cell Plans $10 Million Financing Through European Subsidiary
International Stem Cell Corporation announced that it had entered into a Memorandum of Understanding with ARG Vermogensverwaltung AG, a German Investment Fund, to create a new European subsidiary to be funded with up to $10 million of capital derived from ARG and other independent sources in Europe. [International Stem Cell Corporation Press Release]

Sickle Cell Treatment Developed at LA BioMed Enters Phase III Clinical Trial
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase III clinical trials. [Los Angeles Biomedical Research Institute Press Release]

FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma
Biovest International, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. [Biovest International, Inc. Press Release]


Senate Spending Panel Approves $1 Billion Boost for NIH
A Senate subcommittee matched President Barack Obama’s request for a $1 billion increase in 2011 for the National Institutes of Health (NIH). That raise would bring the agency’s total budget to $32 billion, or 3.5% above the 2010 level, according to a statement from the Senate appropriations labor, health, and human services subcommittee. [National Institutes of Health, United States]

NIH Takes on New Role in Fight Against Rare Diseases
A government program focusing on rare diseases, the Therapeutics for Rare and Neglected Diseases (TRND) program, has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs. TRND will work together with scientists, advocates and others to do the required research and testing on drugs before a compound can be tried in humans in a clinical trial. [National Institutes of Health, United States]

NIH Asks for Input on Closing Loophole in Conflict-of-Interest Rule
Responding to yet another flap about the influence of drug companies on biomedical research, the National Institutes of Health (NIH) has decided it needs more time to revise its rules for policing conflicts of interest so that sanctions will move with an investigator if he or she changes institutions. [National Institutes of Health, United States]

Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors [Docket Number NIH-2010-0001] [Department of Health and Human Services, United States]

National Institute of General Medical Sciences; Notice of Closed Meeting (Doc. 2010-18088) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (Doc. 2010-18052) [National Institutes of Health, United States]

Instrument Development for Biomedical Applications (R21) (RFA-RR-10-009) [National Institutes of Health, United States]

Bioengineering Research Partnerships (BRP)[R01] (PAR-10-234) [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering Program Project (P01) Applications (PAR-10-233) [National Institutes of Health, United States]

EVENTS (Listed by Date)

Cold Spring Harbor Workshop on Stem Cells
July 30-August 5, 2010
Cold Spring Harbor, United States

9th Mount Desert Island Stem Cell Symposium
August 6-7, 2010
Salsbury Cove, United States

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

International Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress
September 27-29, 2010
Doha, Qatar

5th Annual Meeting of the German Society for Stem Cell Research
September 30-October 2, 2010
Lübeck, Germany

AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

5th Annual Translational Stem Cell Research Conference
October 12-13, 2010
New York City, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

World Cord Blood Congress
November 4-7, 2010
Marseille, France

NEW Cambridge Healthtech Institute’s Inaugural Stem Cells in Drug Discovery and Development
November 8-9, 2010
San Diego, United States

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

Stem Cell Network’s 10th Annual Scientific Meeting
November, 22-24, 2010
Calgary, Alberta

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cord Blood News.

here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives  |  Events  |  Subscribe  |  Contact Us